Christi M J Steendam (C M J Steendam)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 8

Top Topics

Pulmonary Artery

Circulating Tumor

Ejection Fraction

Top Venues

CPT: pharmacometrics & systems pharmacology

Therapeutic advances in medical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Bram C Agema, G D Marijn Veerman, Christi M J Steendam, Daan A C Lanser, Tim Preijers, Cor van der Leest, Birgit C P Koch, Anne-Marie C Dingemans, Ron H J Mathijssen, Stijn L W Koolen
Improving the tolerability of osimertinib by identifying its toxic limit. Therapeutic advances in medical oncology 14 (2022)
Christi M J Steendam, A L Diederik, A Dendooven, R J Snijder, G J Herder
Pulmonary artery aneurysms and thrombi. Thorax 72 (12) (2017)